Published in Ann Fam Med on May 12, 2009
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial) | NCT00002540
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ (2014) 3.46
Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One (2010) 1.66
UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax (2011) 1.62
Principles of cancer screening: lessons from history and study design issues. Semin Oncol (2010) 1.52
Time to benefit for colorectal cancer screening: survival meta-analysis of flexible sigmoidoscopy trials. BMJ (2015) 1.43
Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination. J Natl Cancer Inst (2012) 1.27
Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials. Rev Urol (2009) 1.12
Potential of soluble CD26 as a serum marker for colorectal cancer detection. World J Clin Oncol (2011) 1.04
Array-based sensing of normal, cancerous, and metastatic cells using conjugated fluorescent polymers. J Am Chem Soc (2010) 1.04
Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst (2012) 0.96
Evidence, values, guidelines and rational decision-making. J Gen Intern Med (2011) 0.94
Screening tests: a review with examples. Inhal Toxicol (2014) 0.94
Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer. Gynecol Oncol (2011) 0.93
Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST). J Med Screen (2011) 0.89
A model of the influence of false-positive mammography screening results on subsequent screening. Health Psychol Rev (2010) 0.89
False-positive screening results in the Finnish prostate cancer screening trial. Br J Cancer (2010) 0.87
Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer. J Transl Med (2015) 0.82
Chemical nose sensors: an alternative strategy for cancer diagnosis. Expert Rev Mol Diagn (2013) 0.81
Identification of potential glycan cancer markers with sialic acid attached to sialic acid and up-regulated fucosylated galactose structures in epidermal growth factor receptor secreted from A431 cell line. Mol Cell Proteomics (2013) 0.80
Diagnostic accuracy of FDG-PET cancer screening in asymptomatic individuals: use of record linkage from the Osaka Cancer Registry. Int J Clin Oncol (2014) 0.78
Short-term Follow-up US Leads to Higher False-positive Results Without Detection of Structural Recurrences in PTMC. Medicine (Baltimore) (2016) 0.77
Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks). Can Urol Assoc J (2011) 0.76
Cancer screening trials: nuts and bolts. Semin Oncol (2010) 0.76
Risk perception and psychological morbidity in men at elevated risk for prostate cancer. Curr Oncol (2015) 0.75
High-Throughput Analysis of Plasma Hybrid Markers for Early Detection of Cancers. Proteomes (2014) 0.75
Sources of variation in follow-up expenditure after radical cystectomy. Urol Oncol (2015) 0.75
In this issue: the science, art, and policy of primary care. Ann Fam Med (2009) 0.75
Prostate specific antigen: the past, present and future. Curr Urol (2013) 0.75
Analysis of binary responses with outcome-specific misclassification probability in genome-wide association studies. Appl Clin Genet (2016) 0.75
Nonmedical information seeking amid conflicting health information: negative and positive effects on prostate cancer screening. Health Commun (2015) 0.75
Have screening harms become newsworthy? News coverage of prostate and colorectal cancer screening since the 2008 USPSTF recommendation changes. J Behav Med (2014) 0.75
Diagnostic PET Imaging of Mammary Microcalcifications using (64)Cu-DOTA-alendronate in a Rat Model of Breast Cancer. J Nucl Med (2017) 0.75
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin (2008) 12.90
Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med (1998) 12.20
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 10.99
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials (2000) 6.17
Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet (2002) 5.04
How many endoscopies are performed for colorectal cancer screening? Results from CDC's survey of endoscopic capacity. Gastroenterology (2004) 4.69
Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med (2007) 4.68
Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. JAMA (2006) 3.40
Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2007) 3.24
Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"--SCORE. J Natl Cancer Inst (2002) 3.00
Ovarian volume related to age. Gynecol Oncol (2000) 2.61
Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst (2000) 2.53
Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst (2005) 2.27
Lead time associated with screening for prostate cancer. Int J Cancer (2004) 1.93
Predicting the risk of a false-positive test for women following a mammography screening programme. J Med Screen (2007) 1.83
The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program. Cancer (2004) 1.62
PRO: Patients with polyps smaller than 1 cm on computed tomographic colonography should be offered colonoscopy and polypectomy. Am J Gastroenterol (2005) 1.61
Colon cancer screening in 2005: status and challenges. Gastroenterology (2005) 1.54
Estimating the cumulative risk of a false-positive test in a repeated screening program. Biometrics (2004) 1.27
Breast screening: the psychological sequelae of false-positive recall in women with and without a family history of breast cancer. Eur J Cancer (1998) 1.17
Design and evolution of the data management systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 1.11
Cancer screening in theory and in practice. J Clin Oncol (2005) 1.06
The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise. Urol Oncol (2004) 1.03
Coordination and management of a large multicenter screening trial: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 1.02
The economic impact of false-positive cancer screens. Cancer Epidemiol Biomarkers Prev (2004) 1.01
Estimating the cumulative risk of a false-positive under a regimen involving various types of cancer screening tests. J Med Screen (2008) 0.87
Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 0.81
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA (2007) 7.93
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med (2013) 5.92
Long-term mortality after screening for colorectal cancer. N Engl J Med (2013) 5.81
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
A common standard for conflict of interest disclosure in addiction journals. Addiction (2009) 5.62
Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol (2004) 5.38
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med (2014) 4.76
Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med (2013) 4.64
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol (2004) 4.51
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology (2005) 4.31
New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85
Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA (2003) 3.82
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol (2006) 3.81
Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med (2010) 3.79